Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | -47.35% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.09 | N/A | -47.35% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized the importance of their ongoing research and development efforts.
Management did not provide specific guidance for future quarters.
The company is focusing on its pipeline and upcoming projects.
Ionis Pharmaceuticals reported a loss that was worse than expected, which contributed to an 8.09% drop in its stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. The focus on pipeline projects indicates that management is prioritizing long-term growth despite current challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Haemonetics Corporation